View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2020	May 13, 2020
Document Information [Line Items]
Entity Registrant Name	WINDTREE THERAPEUTICS INC /DE/
Entity Central Index Key	0000946486
Trading Symbol	wint
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		13,697,395
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(g) Security	Common Stock, $0.001 par value

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 16,799	$ 22,578
Prepaid expenses and other current assets	1,299	1,283
Total current assets	18,098	23,861
Property and equipment, net	756	798
Restricted cash	154	154
Operating lease right-of-use assets	1,213	1,390
Intangible assets	77,090	77,090
Goodwill	15,682	15,682
Total assets	112,993	118,975
Current Liabilities:
Accounts payable	1,401	1,708
Collaboration and device development payable, net	1,867	1,972
Accrued expenses	2,971	3,226
Operating lease liabilities - current portion	700	750
Loans payable - current portion		161
Total current liabilities	6,939	7,817
Operating lease liabilities - non-current portion	654	794
Loans payable - non-current portion	4,551	4,608
Restructured debt liability - contingent milestone payments	15,000	15,000
Deferred tax liabilities	15,759	15,821
Total liabilities	42,903	44,040
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2020 and December 31, 2019
Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2020 and December 31, 2019; 13,697,419 shares issued at March 31, 2020 and December 31, 2019; 13,697,395 shares outstanding at March 31, 2020 and December 31, 2019	14	14
Additional paid-in capital	764,786	763,097
Accumulated deficit	(691,656)	(685,122)
Treasury stock (at cost); 24 shares	(3,054)	(3,054)
Total stockholders' equity	70,090	74,935
Total liabilities & stockholders' equity	$ 112,993	$ 118,975

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	13,697,419	13,697,419
Common stock, shares outstanding (in shares)	13,697,395	13,697,395
Treasury stock, shares (in shares)	24	24

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues		$ 40
Expenses:
Research and development	3,461	3,342
General and administrative	3,242	3,355
Total operating expenses	6,703	6,697
Operating loss	(6,703)	(6,657)
Other income / (expense):
Interest income	89	60
Interest expense	(44)	(136)
Other income, net	124	196
Other income / (expense), net	169	120
Net loss	$ (6,534)	$ (6,537)
Net loss per common share Basic and diluted (in dollars per share)	$ (0.48)	$ (0.61)
Weighted average number of common shares outstanding Basic and diluted (in shares)	13,697	10,714
License [Member]
Revenues		$ 40

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss	$ (6,534)	$ (6,537)
Other comprehensive income:
Unrealized gain on marketable securities		40
Comprehensive loss	$ (6,534)	$ (6,497)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018	10,711,000
Balance at Dec. 31, 2018	$ 11	$ 728,804	$ (657,647)		$ (3,054)	$ 68,114
Net loss			(6,537)			(6,537)
Vesting of restricted stock units (in shares)	18,000
Vesting of restricted stock units
Withholding tax payments related to net share settlements of restricted stock units		(151)				(151)
Stock-based compensation expense		1,530				1,530
Unrealized gain on marketable securities				40		40
Balance (in shares) at Mar. 31, 2019	10,729,000
Balance at Mar. 31, 2019	$ 11	730,183	(664,184)	40	$ (3,054)	$ 62,996
Balance (in shares) at Dec. 31, 2019	13,697,000					13,697,395
Balance at Dec. 31, 2019	$ 14	763,097	(685,122)		$ (3,054)	$ 74,935
Net loss			(6,534)			(6,534)
Stock-based compensation expense		1,689				1,689
Unrealized gain on marketable securities
Balance (in shares) at Mar. 31, 2020	13,697,000					13,697,395
Balance at Mar. 31, 2020	$ 14	$ 764,786	$ (691,656)		$ (3,054)	$ 70,090

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (6,534)	$ (6,537)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of deferred revenue		(40)
Depreciation	42	50
Amortization of debt discount	3	55
Stock-based compensation	1,689	1,530
Non-cash lease expense	177	192
Realized gain on investments		(11)
Changes in:
Prepaid expenses and other current assets	(16)	5
Accounts payable	(307)	(2,003)
Collaboration and device development payable	(108)	(692)
Accrued expenses	(238)	(1,118)
Operating lease liabilities	(190)	(214)
Other liabilities		24
Net cash used in operating activities	(5,482)	(8,759)
Cash flows from investing activities:
Purchase of property and equipment		(74)
Proceeds from sale of marketable securities		499
Net cash provided by investing activities		425
Cash flows from financing activities:
Principle payments on loans payable	(199)	(447)
Payment for taxes related to net share settlements of restricted stock units		(151)
Net cash used in financing activities	(199)	(598)
Effect of exchange rate changes on cash and cash equivalents	(98)	(202)
Net decrease in cash and cash equivalents	(5,779)	(9,134)
Cash, cash equivalents and restricted cash - beginning of period	22,732	11,358
Cash, cash equivalents and restricted cash - end of period	$ 16,953	$ 2,224

Note 1 - The Company and Description of Business

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note

–

The Company and Description of Business

We are a clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Our development programs are primarily focused in the treatment of acute cardiovascular and pulmonary diseases. Our lead cardiovascular product candidate, istaroxime, a

first

-in-class, dual-acting agent being developed to improve cardiac function in patients with acute heart failure, or AHF, and cardiogenic shock with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in diastolic and systolic function in phase

clinical trials and has been granted Fast Track designation for the treatment of AHF by the U.S. Food and Drug Administration, or FDA. Our lead pulmonary product candidate is AEROSURF (lucinactant for inhalation), a novel drug/medical device combination for non-invasive delivery of our proprietary aerosolized

KL4

surfactant, using our proprietary Aerosol Delivery System, or ADS, technology for the treatment of respiratory distress syndrome, or RDS, in premature infants. AEROSURF has been granted Fast Track designation by the FDA for the treatment of RDS. We are also developing plans to study our proprietary

KL4

surfactant for treatment of lung injury resulting from severe novel coronavirus, or COVID-

19,

infections, if we are able to secure the required additional capital resources necessary to initiate and complete the study. Our other drug product candidates include rostafuroxin, a novel medicine for the treatment of hypertension, in patients with a specific genetic profile. We also have a number of pipeline preclinical product candidates that we are evaluating for progression into clinical development. We are pursuing a number of early exploratory research programs to identify potential product candidates, including oral and intravenous SERCA

heart failure compounds and other product candidates utilizing our

KL4

surfactant and ADS technologies.

December 2018,

we acquired CVie Investments Limited, or CVie Investments, an exempted company with limited liability incorporated under the laws of the Cayman Islands, which we refer to herein as the CVie Acquisition. Since the CVie Acquisition, we have operated CVie Investments, and its wholly-owned subsidiary, CVie Therapeutics, a Taiwan corporation organized under the laws of the People’s Republic of China, as a subsidiary focused on the development of drug product candidates for cardiovascular diseases.

The reader is referred to, and encouraged to read in its entirety, “Item

– Business” in our Annual Report on Form

-K for the year ended

December 31, 2019

that we filed with the Securities and Exchange Commission (SEC) on

April 3, 2020,

which contains a discussion of our business and business plans, as well as information concerning our proprietary technologies and our current and planned development programs.

Note 2 - Basis of Presentation

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Basis of Accounting [Text Block]

Note

–

Basis of Presentation

These interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, for interim financial information in accordance with the instructions to Form

-Q and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries. Accordingly, they do

not

include all of the information and footnotes required by US GAAP for complete consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. When necessary, prior year’s condensed consolidated financial statements have been reclassified to conform to the current year presentation. Operating results for the

three

months ended

March 31, 2020

are

not

necessarily indicative of the results that

may

be expected for the year ending

December 31, 2020.

There have been

changes to our significant accounting policies since

December 31, 2019.

The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with annual audited consolidated financial statements and related notes as of and for the year ended

December 31, 2019

contained in our Annual Report on Form

-K for the year ended

December 31, 2019.

The interim unaudited condensed consolidated financial statements reflect the

-for-

reverse split of our common stock that was approved by our Board of Directors and controlling stockholders and made effective on

April 29, 2020.

All share and per share information data herein that relates to our common stock prior to the effective date has been retroactively restated to reflect the reverse stock split.

Note 3 - Liquidity Risks and Management's Plans

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Liquidity Disclosures [Text Block]

Note

–

Liquidity Risks and Management’s Plans

We are subject to risks common to companies in the biotechnology industry, including but

not

limited to, the need for additional capital, risks of failure of preclinical and clinical studies, the need to obtain marketing approval and reimbursement for any drug product candidate that we

may

identify and develop, the need to successfully commercialize and gain market acceptance of our product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, and reliance on

third

party manufacturers.

We have incurred net losses since inception. Our net loss was

$6.5

million for each of the

three

-month periods ended

March 31, 2020

and

2019.

We expect to continue to incur operating losses for at least the next several years. As of

March 31, 2020,

we had an accumulated deficit of

$691.7

million. Our future success is dependent on our ability to identify and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital, and accordingly, our ability to execute our future operating plans.

In the future, we will need to raise additional capital to continue funding our operations. We plan to obtain funding through a combination of public or private equity offerings, or strategic transactions including collaborations, licensing arrangements or other strategic partnerships. There is inherent uncertainty associated with these fundraising activities and, other than the funding recently committed by Lee’s Pharmaceutical (HK) Ltd., or Lee’s (HK), as discussed below, they are

not

considered probable. In the absence of such funding, we plan to strategically manage our uncommitted spend to execute our priorities and implement cost saving measures to reduce research and development expenditures which would include limiting or delaying or terminating preclinical and clinical studies or other development activities for our AEROSURF product candidates.

We recently entered into a binding commitment with Lee’s (HK), pursuant to which Lee’s (HK) will provide financing for the development of AEROSURF beginning

April 1, 2020

through

September 30, 2020.

We are in the process of negotiating a definitive agreement with Lee’s (HK) to set forth additional funding beyond

September 30, 2020

through study completion. If we are unsuccessful at finalizing a definitive agreement with Lee’s (HK) or if we are successful but Lee’s (HK) subsequently terminates the agreement beyond

September 30, 2020,

our Board of Directors has approved a plan to suspend or terminate AEROSURF development until such time as we are able to secure the capital required to fund the program.

Management considers the successful implementation of these plans and efforts to manage uncommitted spending, including AEROSURF development, and to carry out necessary cost saving measures to be probable. Therefore, we expect our plans will enable our cash and cash equivalents as of the filing of our Quarterly Report on Form

-Q for the

three

months ended

March 31, 2020

to be sufficient to fund operations through at least the next

twelve

months.

Our funding requirements, however, are based on estimates that are subject to risks and uncertainties and

may

change as a result of many factors currently unknown. Although management continues to pursue the plans described above, there is

assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, including as a result of market volatility following the COVID-

pandemic. Until such time as we can generate substantial product revenues, if ever, we expect to finance our cash needs through a combination of equity offerings, strategic partnerships and licensing arrangements. The terms of any future financing

may

adversely affect the holdings or the rights of our existing stockholders.

Note 4 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Note

–

Summary of Significant Accounting Policies

Principles of

onsolidation

The interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments Limited, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).

Goodwill and

ntangible

ssets

We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development, or IPR&D, assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is

not

amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value

may

be impaired. The following table represents identifiable intangible assets as of

March 31, 2020

and

December 31, 2019:

(in thousands)	Carrying Value

Istaroxime drug candidate	$	22,340
Rostafuroxin drug candidate		54,750
Total	$	77,090

Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is

not

amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate its carrying value

may

be impaired.

Foreign

urrency

ransactions

The functional currency for our foreign subsidiaries is US Dollars. We remeasure monetary assets and liabilities that are

not

denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in other income (expense). Foreign currency transactions resulted in gains of approximately

$0.2

million for each of the

three

-month periods ended

March 31, 2020

and

2019.

Use of

stimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments, money market funds, and U.S. Treasury notes with a maturity from date of purchase of

days or less that are readily convertible into cash.

Restructured

ebt

iability –

ntingent

ilestone

ayment

In conjunction with the

November 2017

restructuring and retirement of long-term debt (see, - Note

- Restructured Debt Liability), we have established a

$15.0

million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of

October 27, 2017,

or Exchange and Termination Agreement, between ourselves and affiliates of Deerfield Management Company L.P., or Deerfield. The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are

not

achieved and the liability is written off as a gain on debt restructuring.

Research and

evelopment

We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic

730,

Research and Development

Net

oss per

ommon

hare

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of

March 31, 2020

and

2019,

the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants was

6.5

million and

5.1

million shares, respectively. For the

three

months ended

March 31, 2020

and

2019,

all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.

Income

axes

We account for income taxes in accordance with ASC Topic

740,

Accounting for Income Taxes

, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.

We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is

not

assured.

COVID-

We are subject to risks and uncertainties as a result of the COVID-

pandemic. As of the date of issuance of these interim unaudited condensed consolidated financial statements, our operations, capital and financial resources and overall liquidity position and outlook have

not

been significantly impacted by COVID-

19.

However, we cannot at this time predict the specific extent, duration, or full impact that the COVID-

pandemic will have on our financial condition and operations, including ongoing and planned clinical trials. We believe there could be an impact on the clinical development of our product candidates, which

may

include potential delays, halts or modifications to our ongoing and planned trials.

We are

not

aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities as of the date of issuance of these interim unaudited condensed consolidated financial statements. These estimates

may

change, as new events occur and additional information is obtained. Actual results

may

differ from these estimates under different assumptions or conditions and such differences

may

be material.

Recently Issued Accounting Standards

Recently Adopted Accounting Standards

August 2018,

the FASB issued Accounting Standards Update, or ASU,

2018

13,

Fair Value Measurement

(Topic

820

Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

, or ASU

2018

13,

which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic

820.

Companies will

longer be required to disclose the amount of and reasons for transfers between Level

and Level

of the fair value hierarchy as well as the valuation processes of Level

fair value measurements. However, companies will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level

fair value measurements and the range and weighted average of assumptions used to develop significant unobservable inputs for Level

fair value measurements. ASU

2018

is effective for fiscal years, and interim periods within those fiscal years, beginning after

December 15, 2019.

The amendments relating to additional disclosure requirements will be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments will be applied retrospectively to all periods presented upon their effective date. We adopted ASU

2018

during the quarter ended

March 31, 2020

and the adoption did

not

have an impact on our financial statement disclosures.

Recent Accounting Pronouncements

December 2019,

the FASB issued ASU

2019

12,

Income Taxes

(Topic

740

): Simplifying the Accounting for Income Taxes

, or ASU

2019

12.

ASU

2019

simplifies the accounting for income taxes by removing exceptions within the general principles of Topic

740

regarding the calculation of deferred tax liabilities, the incremental approach for intra-period tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax). which is partially based on income, evaluating tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The ASU is effective for fiscal years beginning after

December 15, 2020

and will be applied either retrospectively or prospectively based upon the applicable amendments. Early adoption is permitted. We are still evaluating the impact this standard will have on our consolidated financial statements and related disclosures, but do

not

believe there will be a material impact upon adoption.

Note 5 - Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note

–

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on

three

levels of inputs, of which the

first

two

are considered observable and the last unobservable, as follows:

	●	Level 1 – Quoted prices in active markets for identical assets and liabilities.
	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value on a Recurring Basis

The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

	Fair Value		Fair value measurement using
	March 31,
(in thousands)	2020		Level 1		Level 2		Level 3

Cash equivalents:
Money market funds	$	15,596	$	15,596		-		-
Total Assets	$	15,596	$	15,596	$	-	$	-

	Fair Value		Fair value measurement using
	December 31,
(in thousands)	2019		Level 1		Level 2		Level 3

Cash equivalents:
Money market funds	$	1,819	$	1,819	$	-	$	-
U.S. Treasury notes		18,230		18,230		-		-
Total Assets	$	20,049	$	20,049	$	-	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 6 - Collaboration and Device Development Payable

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note

–

Collaboration and Device Development Payable

Restructuring of the Battelle Payables

March 2020,

we entered into the

first

amendment to the

December 2018

payment restructuring agreement, or the Amendment, with Battelle Memorial Institute, or Battelle, in which we agreed to amend the payment terms of

two

milestone payments previously due

later than

January 2020.

Under the Amendment, we agreed that (i) the

first

milestone payment would continue to be due upon enrollment of the

first

patient in the next AEROSURF clinical study but

later than

April 15, 2020;

and, (ii) the

second

milestone payment would continue to be due upon completion of technology transfer of our device manufacturing process for the phase

ADS to our new medical device manufacturer but

later than

September 1, 2020.

The Amendment is treated as a debt modification and, in accordance with debt modification accounting,

gain or loss was recognized.

April 2020,

we made the

first

milestone payment of

$0.8

million to Battelle and announced enrollment of the

first

patient into the AEROSURF phase

bridging study.

Note 7 - Loans Payable

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Short-term Debt [Text Block]

Note

–

Loan

Payable

Loans Payable – Current Portion

Loan payable to Bank Direct Capital Finance

May 2019,

we entered into an insurance premium financing and security agreement with Bank Direct Capital Finance, or Bank Direct. Under the agreement, we have financed

$0.7

million of certain premiums at a

5.35%

annual interest rate. As of

December 31, 2019,

the outstanding principal of the loan was

$0.2

million. The balance of the loan was repaid during the quarter ended

March 31, 2020.

Loans Payable – Non-current Portion

Assumption of bank debt as part of the CVie Acquisition

As part of the CVie Acquisition, we assumed approximately

$4.5

million in a bank credit facility.

September 2016,

CVie Therapeutics Limited entered into a

-month revolving credit facility of approximately

$2.9

million with O-Bank Co., Ltd., or O-Bank, to finance operating activities, or the O-Bank Facility. The O-Bank Facility was later renewed and increased to approximately

$5.8

million in

September 2017.

The O-Bank Facility was guaranteed by Lee’s Pharmaceutical Holdings Limited, or Lee’s, which pledged bank deposits in the amount of

110%

of the actual borrowing amount. The guaranty was part of the O-Bank Facility; however, we do

not

have a written commitment from Lee’s to maintain the collateral. Interest, payable in cash on a monthly basis, is determined based on the

-day Taipei Interbank Offer Rate, or TAIBOR, plus

0.91%.

The O-Bank Facility expired on

September 11, 2019

and the loans were set to mature

six

months after the expiration date, on

March 11, 2020.

March 2020,

the O-Bank Facility was amended, among other things, to extend the maturity date to

March 2022,

to decrease the total amount of the O-Bank Facility to approximately

$5.0

million, to change the applicable interest rate to the TAIBOR plus

1.17%

and to adjust the term to

-month non-revolving. All amounts due under the O-Bank Facility will be payable upon the earlier of (i)

six

months after the expiration date or (ii)

two

years after the drawdown date.

As of

March 31, 2020

and

December 31, 2019,

the outstanding principal of the O-Bank Facility was approximately

$4.6

million.

Note 8 - Restructured Debt Liability

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Long-term Debt [Text Block]

Note

–

Restructured Debt Liability

November 1, 2017,

we and Deerfield entered into an Exchange and Termination Agreement pursuant to which (i) promissory notes evidencing a loan with affiliates of Deerfield Management Company L.P., or Deerfield Loan, in the aggregate principal amount of

$25.0

million and (ii) warrants to purchase up to

8,333

shares of our common stock at an exercise price of

$2,360.40

per share held by Deerfield were cancelled in consideration for (i) a cash payment in the aggregate amount of

$2.5

million, (ii)

23,703

shares of common stock, representing

of fully-diluted shares outstanding (as defined in the Exchange and Termination Agreement) on the closing date, and (iii) the right to receive certain milestone payments based on achievement of specified AEROSURF development and commercial milestones, which, if achieved, could potentially total up to

$15.0

million. In addition, a related security agreement, pursuant to which Deerfield held a security interest in substantially all of our assets, was terminated. We established a

$15.0

million long-term liability for the contingent milestone payments potentially due to Deerfield under the Exchange and Termination Agreement (see, Note

- Accounting Policies and Recent Accounting Pronouncements). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are

not

achieved and the liability is written off as a gain on debt restructuring.

As of

March 31, 2020

and

December 31, 2019,

the restructured debt liability balance was

$15.0

million.

Note 9 - Stock Options and Stock-based Employee Compensation

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

Note

–

Stock Options and Stock-Based Employee Compensation

We recognize in our condensed consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically

three

years. We recognize restricted stock unit awards to employees and non-employee directors based on their fair value on the date of grant. Compensation expense related to restricted stock unit awards is recognized ratably over the vesting period, which typically has been between approximately

six

months.

A summary of activity under our long-term incentive plan is presented below:

(in thousands, except for weighted-average data)				Weighted- Average Exercise		Weighted- Average Remaining Contractual
Stock Options	Shares			Price		Term (In Yrs)

Outstanding at January 1, 2020		1,772		$	17.61
Forfeited or expired		(7	)		65.17
Outstanding at March 31, 2020		1,765		$	17.40		8.7

Vested and exercisable at March 31, 2020		599		$	26.66		8.7

Vested and expected to vest at March 31, 2020		1,696		$	17.37		8.8

There was

activity during the quarter with respect to restricted stock units.

The table below summarizes the total stock-based compensation expense included in the interim unaudited condensed consolidated statements of operations for the periods presented:

	Three Months Ended March 31,
(in thousands)	2020		2019

Research and development	$	714	$	489
General and administrative		975		1,041
Total	$	1,689	$	1,530

Note 10 - Collaboration, Licensing and Research Funding Agreements

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Corporate Partnership, Licensing and Research Funding Agreements [Text Block]

Note

–

Collaboration, Licensing and Research Funding Agreements

March 18, 2020,

we entered into a binding term sheet, or the Term Sheet, with Lee’s (HK), pursuant to which the parties agreed that Lee’s (HK) would provide financing for the continued development of our product candidate, AEROSURF. The Term Sheet provides that in connection with the development of AEROSURF, Lee’s (HK) will make non-refundable payments to us in the amount of (i)

$1.0

million

later than

April 1, 2020; (

ii)

$1.4

million

later than

July 1, 2020;

and (iii)

$1.5

million

later than

September 1, 2020;

provided, however, that the amount of the last payment will be reduced to

$0.4

million if on or prior to

August 31, 2020, (

i) we receive net proceeds from the sale of our equity securities of at least

$4.5

million and (ii) our common stock becomes listed on the Nasdaq Capital Market. The parties have agreed that they will negotiate in good faith to determine the terms of a definitive agreement prior to

September 30, 2020.

The definitive agreement will set forth additional semi-annual, non-refundable payments to fund the continued development of AEROSURF after

September 30, 2020.

April 2020,

we received the

first

$1.0

million non-refundable payment.

The Term Sheet provides that, until such time as we have repaid

125%

of the amounts funded by Lee’s (HK) for the development of AEROSURF, we will pay to Lee’s (HK)

50%

of all revenue amounts and payments received by us for any sale, divestiture, license or other development and/or commercialization of the

KL4/AEROSURF

patent portfolio, excluding (i) payments for bona fide research and development services; (ii) reimbursement of patent expenses; and (iii) all amounts paid to us under the License, Development and Commercialization Agreement between us and Lee’s (HK) dated as of

June 12, 2017,

as amended, or the License Agreement, and subject to reduction for any payments made by us with respect to

third

-party intellectual property

not

previously funded by Lee’s (HK).

The Term Sheet also provides that we and Lee’s (HK) will amend existing provisions of the License Agreement to reduce future royalty payments payable to us from Lee’s (HK) on net sales of certain licensed products, reducing the range of such royalty payment percentage from a range of high single to low mid-double digits to a range of mid-single to low-double digits.

We have determined that the Term Sheet is within the scope of ASC

730

20,

Research and Development Arrangements

, or ASC

730

20.

We concluded that there has

not

been a substantive and genuine transfer of risk related to the Term Sheet as there is a presumption that we are obligated to repay Lee’s (HK) based on the significant related party relationship that exists at the time the parties entered into the Term Sheet, including Lee’s (HK)’s approximate

35%

ownership of the outstanding shares of our common stock.

We have determined that the appropriate accounting treatment under ASC

730

is to record the proceeds received from Lee’s (HK) as cash and cash equivalents, as we have the ability to direct the usage of funds, and a long-term liability on our condensed consolidated balance sheet when received. The liability will remain on the balance sheet until we repay such amounts as a result of any revenues and payments received by us for any sale, divestiture, license or other development and/or commercialization of the

KL4/AEROSURF

patent portfolio, as defined in the Term Sheet, or through the reduction of future milestone payments or royalties payable by Lee’s (HK) to us under the existing License Agreement, as amended by the Term Sheet.

We have also determined that the Term Sheet is

not

in its entirety a derivative under the scope of ASC

815,

Derivatives and Hedging

, or ASC

815,

due to the scope exception under ASC

815

59,

nor are there any embedded derivatives that require separate accounting.

Note 11 - Subsequent Events

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Subsequent Events [Text Block]

Note

–

Subsequent Events

Series F Warrant Amendment

April 24, 2020,

we and each of the holders of our Series F Warrants, or the Series F Warrants, entered into Amendment

No.

to the Series F Warrants whereby the expiration date of the Series F Warrants was extended from

June 24, 2020

December 24, 2020

in consideration for the holders agreeing to be bound by a lock-up provision with respect to any shares of common stock or securities convertible, exchangeable or exercisable into shares of common stock that are beneficially owned, held or acquired by the holders. The lock-up provision provides that the holders will

not

offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of our securities for a period of

days following the earlier of (i) the closing date of our next public offering of securities, or (ii)

December 24, 2020.

Series I Warrant Amendment

May 6, 2020,

we and certain holders of our Series I Warrants, or the Series I Warrants, entered into Amendment

No.

to the Series I Warrants pursuant to which the exercise price of the Series I Warrants was amended from

$12.09

$9.67

if the Series I Warrants are exercised, in whole or in part, prior to

December 5, 2021.

In addition, the certain holders of the Series I Warrants agreed to be bound by a lockup provision with respect to any shares of our common stock or securities convertible, exchangeable or exercisable into shares of common stock that are beneficially owned, held or acquired by such holders for a period of

days following the earlier of (i) the closing date of our next public offering of securities, or (ii)

December 24, 2020.

During the lock-up period, the certain holders of the Series I Warrants will

not

offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of any shares of our common stock or securities convertible, exchangeable or exercisable into shares of our common stock.

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of

onsolidation

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and

ntangible

ssets

not

amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value

may

be impaired. The following table represents identifiable intangible assets as of

March 31, 2020

and

December 31, 2019:

(in thousands)	Carrying Value

Istaroxime drug candidate	$	22,340
Rostafuroxin drug candidate		54,750
Total	$	77,090

Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is

not

amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate its carrying value

may

be impaired.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign

urrency

ransactions

The functional currency for our foreign subsidiaries is US Dollars. We remeasure monetary assets and liabilities that are

not

$0.2

million for each of the

three

-month periods ended

March 31, 2020

and

2019.

Use of Estimates, Policy [Policy Text Block]

Use of

stimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

days or less that are readily convertible into cash.

Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block]

Restructured

ebt

iability –

ntingent

ilestone

ayment

In conjunction with the

November 2017

restructuring and retirement of long-term debt (see, - Note

- Restructured Debt Liability), we have established a

$15.0

million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of

October 27, 2017,

not

achieved and the liability is written off as a gain on debt restructuring.

Research and Development Expense, Policy [Policy Text Block]

Research and

evelopment

730,

Research and Development

Earnings Per Share, Policy [Policy Text Block]

Net

oss per

ommon

hare

March 31, 2020

and

2019,

the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants was

6.5

million and

5.1

million shares, respectively. For the

three

months ended

March 31, 2020

and

2019,

all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.

Income Tax, Policy [Policy Text Block]

Income

axes

We account for income taxes in accordance with ASC Topic

740,

Accounting for Income Taxes

not

assured.

Effect of COVID-19 Pandemic [Policy Text Block]

COVID-

We are subject to risks and uncertainties as a result of the COVID-

not

been significantly impacted by COVID-

19.

However, we cannot at this time predict the specific extent, duration, or full impact that the COVID-

may

include potential delays, halts or modifications to our ongoing and planned trials.

We are

not

may

change, as new events occur and additional information is obtained. Actual results

may

differ from these estimates under different assumptions or conditions and such differences

may

be material.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Standards

Recently Adopted Accounting Standards

August 2018,

the FASB issued Accounting Standards Update, or ASU,

2018

13,

Fair Value Measurement

(Topic

820

Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

, or ASU

2018

13,

which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic

820.

Companies will

longer be required to disclose the amount of and reasons for transfers between Level

and Level

of the fair value hierarchy as well as the valuation processes of Level

fair value measurements. However, companies will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level

fair value measurements and the range and weighted average of assumptions used to develop significant unobservable inputs for Level

fair value measurements. ASU

2018

is effective for fiscal years, and interim periods within those fiscal years, beginning after

December 15, 2019.

2018

during the quarter ended

March 31, 2020

and the adoption did

not

have an impact on our financial statement disclosures.

Recent Accounting Pronouncements

December 2019,

the FASB issued ASU

2019

12,

Income Taxes

(Topic

740

): Simplifying the Accounting for Income Taxes

, or ASU

2019

12.

ASU

2019

simplifies the accounting for income taxes by removing exceptions within the general principles of Topic

740

December 15, 2020

not

believe there will be a material impact upon adoption.

Note 4 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Indefinite-Lived Intangible Assets [Table Text Block]

(in thousands)	Carrying Value

Istaroxime drug candidate	$	22,340
Rostafuroxin drug candidate		54,750
Total	$	77,090

Note 5 - Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value		Fair value measurement using
	March 31,
(in thousands)	2020		Level 1		Level 2		Level 3

Cash equivalents:
Money market funds	$	15,596	$	15,596		-		-
Total Assets	$	15,596	$	15,596	$	-	$	-

	Fair Value		Fair value measurement using
	December 31,
(in thousands)	2019		Level 1		Level 2		Level 3

Cash equivalents:
Money market funds	$	1,819	$	1,819	$	-	$	-
U.S. Treasury notes		18,230		18,230		-		-
Total Assets	$	20,049	$	20,049	$	-	$	-

Note 9 - Stock Options and Stock-based Employee Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

(in thousands, except for weighted-average data)				Weighted- Average Exercise		Weighted- Average Remaining Contractual
Stock Options	Shares			Price		Term (In Yrs)

Outstanding at January 1, 2020		1,772		$	17.61
Forfeited or expired		(7	)		65.17
Outstanding at March 31, 2020		1,765		$	17.40		8.7

Vested and exercisable at March 31, 2020		599		$	26.66		8.7

Vested and expected to vest at March 31, 2020		1,696		$	17.37		8.8

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2020		2019

Research and development	$	714	$	489
General and administrative		975		1,041
Total	$	1,689	$	1,530

Note 2 - Basis of Presentation (Details Textual)	Apr. 29, 2020
Reverse Stock Split [Member] \| Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	3

Note 3 - Liquidity Risks and Management's Plans (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Net Income (Loss) Attributable to Parent, Total	$ (6,534)	$ (6,537)
Retained Earnings (Accumulated Deficit), Ending Balance	$ (691,656)		$ (685,122)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Note 4 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands, shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Nov. 01, 2017
Foreign Currency Transaction Gain (Loss), before Tax, Total	$ 200
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000		$ 15,000
Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants (in shares)	6.5	5.1
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member]
Liability for Contingent Milestone Payment, Noncurrent				$ 15,000

Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Indefinite intangible asset	$ 77,090	$ 77,090
Istaroxime Drug Candidate [Member]
Indefinite intangible asset	22,340
Rostafuroxin Drug Candidate [Member]
Indefinite intangible asset	$ 54,750

Note 5 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Total Assets	$ 15,596	$ 20,049
Fair Value, Inputs, Level 1 [Member]
Total Assets	15,596	20,049
Fair Value, Inputs, Level 2 [Member]
Total Assets
Fair Value, Inputs, Level 3 [Member]
Total Assets
Money Market Funds [Member]
Cash equivalents	15,596	1,819
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash equivalents	15,596	1,819
Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash equivalents
US Treasury Securities [Member]
Cash equivalents		18,230
US Treasury Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash equivalents		18,230
US Treasury Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash equivalents
US Treasury Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash equivalents

Note 6 - Collaboration and Device Development Payable (Details Textual) $ in Millions	1 Months Ended
	Apr. 30, 2020 USD ($)
Subsequent Event [Member]
Payments for Collaboration and Device Development Payable	$ 0.8

Note 7 - Loans Payable (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	Mar. 20, 2020	Sep. 30, 2017	Mar. 31, 2020	Dec. 31, 2019	May 30, 2019	Dec. 21, 2018	Sep. 30, 2016
Loans Payable, Noncurrent, Total			$ 4,551	$ 4,608
O-Bank Co., Ltd. [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Percent of Pledged Deposits Required		110.00%
Loans Payable, Noncurrent, Total			4,600	4,600
O-Bank Co., Ltd. [Member] \| Revolving Credit Facility [Member] \| Taipei Interbank Offer Rate (TAIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		0.91%
O-Bank Co., Ltd. [Member] \| Revolving Credit Facility [Member] \| CVie Investments [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 5,800					$ 2,900
O-Bank Co., Ltd. [Member] \| Nonrevolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 5,000
Debt Instrument, Term (Month)	2 years
O-Bank Co., Ltd. [Member] \| Nonrevolving Credit Facility [Member] \| Taipei Interbank Offer Rate (TAIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	1.17%
CVie Investments [Member] \| O-Bank Co., Ltd. [Member] \| Revolving Credit Facility [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total						$ 4,500
Loan payable to Bank Direct Capital Finance [Member]
Loans Payable to Bank, Total				$ 200
Repayments of Notes Payable			$ 200
Loan payable to Bank Direct Capital Finance [Member] \| Loans Payable [Member]
Debt Instrument, Face Amount					$ 700
Debt Instrument, Interest Rate, Stated Percentage					5.35%

Note 8 - Restructured Debt Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Nov. 01, 2017	Mar. 31, 2020	Dec. 31, 2019
Liability for Contingent Milestone Payment, Noncurrent		$ 15,000	$ 15,000
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member]
Extinguishment of Debt, Amount	$ 25,000
Class of Warrant or Right, Number of Warrants Cancelled (in shares)	8,333
Class of Warrant or Right, Exercise Price of Cancelled Warrants (in dollars per share)	$ 2,360.40
Repayments of Long-term Debt, Total	$ 2,500
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations (in shares)	23,703
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding	2.00%
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000	$ 15,000	$ 15,000

Note 9 - Stock Options and Stock-based Employee Compensation (Details Textual)	3 Months Ended
	Mar. 31, 2020
Restricted Stock Units (RSUs) [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)	180 days
Restricted Stock Units (RSUs) [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)	1 year 180 days
The 2011 Long-term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)	3 years

Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2020 $ / shares shares
Shares Outstanding, Beginning Balance (in shares) \| shares	1,772
Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share) \| $ / shares	$ 17.61
Shares Forfeited or Expired (in shares) \| shares	(7)
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) \| $ / shares	$ 65.17
Shares Outstanding, Ending Balance (in shares) \| shares	1,765
Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share) \| $ / shares	$ 17.40
Weighted Average Remaining Contractual Life, Outstanding (Year)	8 years 255 days
Shares Vested and Exercisable (in shares) \| shares	599
Weighted Average Exercise Price, Vested and Exercisable (in dollars per share) \| $ / shares	$ 26.66
Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)	8 years 255 days
Vested and expected to vest (in shares) \| shares	1,696
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) \| $ / shares	$ 17.37
Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)	8 years 292 days

Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation expense	$ 1,689	$ 1,530
Research and Development Expense [Member]
Stock-based compensation expense	714	489
General and Administrative Expense [Member]
Stock-based compensation expense	$ 975	$ 1,041

Note 10 - Collaboration, Licensing and Research Funding Agreements (Details Textual) - USD ($) $ in Millions		1 Months Ended
	Mar. 18, 2020	Apr. 30, 2020
Lee’s Pharmaceutical Holdings Limited [Member] \| Windtree Therapeutics [Member]
Equity Method Investment, Ownership Percentage	35.00%
Term Sheet With Lee [Member]
Financing of Product, Potential Proceeds from Equity Sale	$ 4.5
Financing of Product, Percent of Financing That Must be Repaid to Discontinue Revenue Sharing	125.00%
Financing of Product, Percent of Revenue Shared With Financer	50.00%
Term Sheet With Lee [Member] \| Subsequent Event [Member]
Proceeds from License Fees Received		$ 1.0
Term Sheet With Lee [Member] \| Payments no Later Than April 1, 2020 [Member]
Proceeds from License Fees Received	$ 1.0
Term Sheet With Lee [Member] \| Payments no Later Than July 1, 2020 [Member]
Proceeds from License Fees Received	1.4
Term Sheet With Lee [Member] \| Payments no Later Than September 1, 2020 [Member]
Proceeds from License Fees Received	1.5
Term Sheet With Lee [Member] \| Reduction of Last Payment if Made Prior to August 31, 2020 [Member]
Proceeds from License Fees Received	$ 0.4

Note 11 - Subsequent Events (Details Textual) - $ / shares	May 06, 2020	May 05, 2020
Series I Warrants [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 9.67	$ 12.09